These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21387672)

  • 1. [Strategy for patients with low-risk coronary artery disease: initial medical therapy only or PCI plus medical therapy].
    Nishigaki K
    Nihon Rinsho; 2011 Feb; 69(2):253-8. PubMed ID: 21387672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study.
    Nishigaki K; Yamazaki T; Kitabatake A; Yamaguchi T; Kanmatsuse K; Kodama I; Takekoshi N; Tomoike H; Hori M; Matsuzaki M; Takeshita A; Shimbo T; Fujiwara H;
    JACC Cardiovasc Interv; 2008 Oct; 1(5):469-79. PubMed ID: 19463347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of the BARI 2D and COURAGE trials: the evolving role of percutaneous coronary intervention.
    Holper EM; Addo T
    Coron Artery Dis; 2010 Nov; 21(7):397-401. PubMed ID: 20634692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balancing benefit against risk in the choice of therapy for coronary artery disease. Lesson from prospective, randomized, clinical trials of percutaneous coronary intervention and coronary artery bypass graft surgery.
    Morrison DA; Sacks J
    Minerva Cardioangiol; 2003 Oct; 51(5):585-97. PubMed ID: 14551526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial).
    Boden WE; O'Rourke RA; Teo KK; Maron DJ; Hartigan PM; Sedlis SP; Dada M; Labedi M; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
    Am J Cardiol; 2009 Jul; 104(1):1-4. PubMed ID: 19576311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies in cardiovascular medicine: Chronic stable coronary artery disease: drugs vs. revascularization.
    Simoons ML; Windecker S
    Eur Heart J; 2010 Mar; 31(5):530-41. PubMed ID: 20106842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal medical therapy is a proven option for chronic stable angina.
    O'Rourke RA
    J Am Coll Cardiol; 2008 Sep; 52(11):905-7. PubMed ID: 18772059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis.
    Katritsis DG; Ioannidis JP
    Circulation; 2005 Jun; 111(22):2906-12. PubMed ID: 15927966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent angina: the Araba Phoenix of cardiology.
    Marzilli M; Huqi A; Morrone D
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():27-32. PubMed ID: 21391731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
    Teo KK; Sedlis SP; Boden WE; O'Rourke RA; Maron DJ; Hartigan PM; Dada M; Gupta V; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
    J Am Coll Cardiol; 2009 Sep; 54(14):1303-8. PubMed ID: 19778673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease.
    Schömig A; Mehilli J; de Waha A; Seyfarth M; Pache J; Kastrati A
    J Am Coll Cardiol; 2008 Sep; 52(11):894-904. PubMed ID: 18772058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of PCI on quality of life in patients with stable coronary disease.
    Weintraub WS; Spertus JA; Kolm P; Maron DJ; Zhang Z; Jurkovitz C; Zhang W; Hartigan PM; Lewis C; Veledar E; Bowen J; Dunbar SB; Deaton C; Kaufman S; O'Rourke RA; Goeree R; Barnett PG; Teo KK; Boden WE; ; Mancini GB
    N Engl J Med; 2008 Aug; 359(7):677-87. PubMed ID: 18703470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424.
    Boden WE; O'rourke RA; Teo KK; Hartigan PM; Maron DJ; Kostuk W; Knudtson M; Dada M; Casperson P; Harris CL; Spertus JA; Shaw L; Chaitman BR; Mancini GB; Berman DS; Weintraub WS;
    Am Heart J; 2006 Jun; 151(6):1173-9. PubMed ID: 16781214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.
    Hueb W; Lopes NH; Gersh BJ; Soares P; Machado LA; Jatene FB; Oliveira SA; Ramires JA
    Circulation; 2007 Mar; 115(9):1082-9. PubMed ID: 17339566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of percutaneous coronary intervention with medication in the treatment of coronary artery disease in hemodialysis patients.
    Yasuda K; Kasuga H; Aoyama T; Takahashi H; Toriyama T; Kawade Y; Iwashima S; Yamada S; Kawahara H; Maruyama S; Yuzawa Y; Ishii H; Murohara T; Matsuo S
    J Am Soc Nephrol; 2006 Aug; 17(8):2322-32. PubMed ID: 16837633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable long-term survival in patients undergoing stent PCI of unprotected left main coronary artery compared to predicted short-term prognosis of CABG estimated by EuroSCORE: clinical determinants of long-term outcome.
    Lehmann R; Spyridopoulos I; Kremer J; Zeiher AM; Schächinger V; Fichtlscherer S
    J Interv Cardiol; 2009 Aug; 22(4):311-9. PubMed ID: 19689656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease.
    Sedlis SP; Jurkovitz CT; Hartigan PM; Goldfarb DS; Lorin JD; Dada M; Maron DJ; Spertus JA; Mancini GB; Teo KK; O'Rourke RA; Boden WE; Weintraub WS;
    Am J Cardiol; 2009 Dec; 104(12):1647-53. PubMed ID: 19962469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization.
    Hordijk-Trion M; Lenzen M; Wijns W; de Jaegere P; Simoons ML; Scholte op Reimer WJ; Bertrand ME; Mercado N; Boersma E;
    Eur Heart J; 2006 Mar; 27(6):671-8. PubMed ID: 16423872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.